BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate

  • BridgeBio Pharma Inc BBIO has announced interim Phase 1 data from healthy volunteers, supporting the development of BBP-671 for pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias. 
  • BBP-671 is being developed as a potential therapy for diseases in which coenzyme-A (CoA) metabolism is deficient, including PKAN, propionic acidemia (PA), and methylmalonic acidemia (MMA).
  • BBP-671 was detected in healthy volunteer plasma and cerebrospinal fluid (CSF), which suggests BBP-671 is entering the brain.
  • Related: BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology.
  • BBP-671 increased whole blood acetyl-CoA levels.
  • The drug was generally well-tolerated following oral dosing in healthy volunteers, with no serious adverse events observed.
  • Mild treatment-related emergent adverse events included headache, abdominal pain, and nausea.
  • Asymptomatic neutropenia was observed in three individuals with repeat dosing of BBP-671.
  • BridgeBio plans to move forward with the second part of its Phase 1 clinical study in patients with PA and MMA in 2H of 2022 and initiate a pivotal Phase 2/3 clinical study in PKAN in 2023.
  • Price Action: BBIO shares are up 0.38% at $6.66 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!